Hims & Hers Health, Inc. (NYSE:HIMS) saw its shares edge 1.5% higher on Monday after unveiling a fresh $250 million stock ...

Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, ...

The Denmark-based company on Monday said it will offer the first two monthly doses of Wegovy and Ozempic for $199 a month to those who pay in cash between now and March 31 of next year. After those ...

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.

Hims & Hers Health (HIMS) announced on Monday an up to $250M share repurchase program of outstanding class A common stock ...

Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Analysts also weigh in on Chesapeake Utilities, Halozyme Therapeutics, Sea Ltd., and Roper Technologies. Trump reverses on tariffs for some imports, Bitcoin falls on details of strategic reserve, ...

This expansion into diagnostics and tailored care represents a logical strategic extension of the company's telehealth model. Yet, the market's focus remained fixed on the worrying traffic and ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.

How Ozempic Is Changing Thanksgiving According to the independent research and polling source KFF, one in eight Americans reported taking a GLP-1 receptor agonist ...